Tag Archives: CEO & Investor Conference

Get the Deep Dish on Biotech at the World Congress

Chicago is my kinda town. Meet me there April 27-30 for the World Congress on Industrial Biotechnology and Bioprocessing. There’s a great lineup of sessions and speakers highlighting the latest in industrial biotechnology.  Now in its fifth year, the Congress continues to grow in size and scope.  This event has something for everyone – session tracks will cover relevant topics in the areas of biofuels and bioenergy; renewable feedstocks; renewable chemicals and biomaterials; fine chemicals; Read More >

Events  |  Leave a comment  |  Email This Post
Tags:

Boston in the Spring Time is Even More Lovely with BIO

BIO will debut a new conference in Boston April 22-23.  The National Venture Conference will draw early-stage, private biotech companies and healthcare venture partners.  I hope to see you there, but in the meantime, check out http://bnvc.bio.org for more details in the coming months.

Events  |  Leave a comment  |  Email This Post
Tags:

Biotech World to Descend on San Diego

The 2008 BIO International Convention is the place to be for anyone covering the life sciences, investments and policy.  If you have attended in the past, you’ll notice a few changes – the day pattern will be Tuesday through Friday, come into town early though for the golf outing. I’ll be dragging my Patti Berg’s to California, should be fun. Check out the new program tracks – Biomarkers, Growing the Biotech Workforce, and International Case Studies.  Join Read More >

Events  |  Leave a comment  |  Email This Post
Tags:

From the Hill to the Street: Examining Policy Issues in Biotech

Without a supportive legislative and regulatory environment, biotech companies cannot raise the funds necessary to get a product to market.  The panelists explored the pressing policy issues which could have a significant impact on the industry, from the creation of a pathway for the approval of follow-on biologics, patent reform, comparative effectiveness and the implementation of the Food and Drug Administration Amendments Act (FDAAA) which was signed into law last year.  The panelists also discussed Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags:

Elusive Cancer Endpoints: How to Survive the Uncertainty

The debate surrounding cancer endpoints has focused on the issue of quality of life and progression. Panelists shared some of the challenges in assessing quality of life, since it can be a fickle and subjective process. The data can be hard to nail down since patients don’t always fill out the forms. The critical issues include survival rates, improved quality of life and progression of disease. Everything must be taken into consideration to determine endpoints, which is why Read More >

Health  |  Leave a comment  |  Email This Post
Tags: